Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating activities:
Net loss	$ (12,395)	$ (74,827)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	7,945	21,847
Depreciation and amortization	1,330	1,457
Amortization of debt discount	180	103
Amortization of debt issuance costs	104
Accretion of discount on short-term investments	(1,211)	(835)
Impairment of property and equipment	3,441	309
Loss on disposal of property and equipment		23
Change in operating assets and liabilities:
Accounts receivable	(13,571)	(24,644)
Inventory	(754)	9,950
Prepaid expenses and other assets	67	10,369
Accounts payable	6,986	(1,268)
Accrued clinical and manufacturing liabilities	(4,605)	(4,587)
Accrued payroll and employee liabilities	(2,139)	(3,560)
Other accrued and other non-current liabilities	502	13,598
Net cash used in operating activities	(14,120)	(52,065)
Investing activities:
Purchases of short-term investments	(65,100)	(28,381)
Maturities and sales of short-term investments	69,063	78,935
Purchases of property and equipment	(637)	(502)
Net cash provided by investing activities	3,326	50,052
Financing activities:
Receipts (Payments) for stock issued under the equity incentive plan	328	(593)
Proceeds from purchases under the employee stock purchase plan	175	704
Net cash provided by financing activities	503	111
Net decrease increase in cash and cash equivalents	(10,291)	(1,902)
Cash and cash equivalents at beginning of year	28,677	15,364
Cash and cash equivalents at end of period	18,386	13,462
Supplemental disclosure of cash flow information:
Interest paid	$ 2,426	$ 1,125